Praxis Investment Management Inc. Invests $155,000 in Core Laboratories Inc. $CLB

Praxis Investment Management Inc. purchased a new position in Core Laboratories Inc. (NYSE:CLB) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 13,420 shares of the oil and gas company’s stock, valued at approximately $155,000.

Other large investors have also recently modified their holdings of the company. Oppenheimer Asset Management Inc. raised its position in shares of Core Laboratories by 19.8% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 69,184 shares of the oil and gas company’s stock worth $1,037,000 after purchasing an additional 11,438 shares during the last quarter. Assetmark Inc. raised its position in Core Laboratories by 92.5% in the 1st quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company’s stock worth $43,000 after buying an additional 1,387 shares during the last quarter. Public Sector Pension Investment Board raised its position in Core Laboratories by 26.9% in the 1st quarter. Public Sector Pension Investment Board now owns 148,476 shares of the oil and gas company’s stock worth $2,226,000 after buying an additional 31,485 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Core Laboratories by 1.3% in the 1st quarter. Envestnet Asset Management Inc. now owns 254,005 shares of the oil and gas company’s stock worth $3,808,000 after buying an additional 3,357 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in Core Laboratories by 2.1% in the 1st quarter. Principal Financial Group Inc. now owns 233,829 shares of the oil and gas company’s stock worth $3,505,000 after buying an additional 4,733 shares during the last quarter. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Core Laboratories Trading Down 0.6%

Shares of CLB stock opened at $11.35 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.27 and a quick ratio of 1.70. The company has a market cap of $532.06 million, a price-to-earnings ratio of 18.30, a PEG ratio of 6.27 and a beta of 1.38. Core Laboratories Inc. has a 1 year low of $9.72 and a 1 year high of $21.83. The firm has a fifty day moving average price of $11.69 and a 200-day moving average price of $11.74.

Core Laboratories (NYSE:CLB) last released its earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.01. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.The company had revenue of $130.16 million for the quarter, compared to the consensus estimate of $129.19 million. During the same period in the previous year, the business earned $0.22 earnings per share. Core Laboratories’s quarterly revenue was down .3% compared to the same quarter last year. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. As a group, equities analysts predict that Core Laboratories Inc. will post 0.96 earnings per share for the current year.

Core Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 25th. Investors of record on Monday, August 4th were paid a dividend of $0.01 per share. The ex-dividend date was Monday, August 4th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.4%. Core Laboratories’s payout ratio is 6.45%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CLB shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Core Laboratories in a research report on Wednesday, October 8th. Stifel Nicolaus decreased their target price on Core Laboratories from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, July 16th. Wall Street Zen raised Core Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. Finally, Zacks Research raised Core Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $12.50.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.